奎扎替尼作为新诊断的FLT3-ITD（+）急性髓系白血病完全缓解患者维持治疗的两个剂量水平的比较研究在中国完成首例受试者给药

参考文献：

1.Siegel RL, Miller KD, Fuchs H, et al. Cancer statistics, 2022. CA Cancer J Clin. 2022;72(1): 7–33.

2.De Kouchkovsky I, Abdul-Hay M. Acute myeloid leukemia: a comprehensive review and 2016 update. Blood Cancer J. 2016;6(7): e441.

3.SEER Cancer Statistics Factsheets. Acute myeloid leukemia. Bethesda MD, Cancer Institute. Available from: https: //seer.cancer.gov/statfacts/html/amyl.html.

4.Lubeck DP, Danese M, Jennifer D, et al. Systematic literature review of the global incidence and prevalence of myelodysplastic syndrome and acute myeloid leukemia. Blood. 2016;128(22): 5930.

5.Heuser M, Ofran Y, Boissel N, et al. Acute myeloid leukaemia in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncol. 2020;31(6): 697-712. Erratum in: Ann Oncol. 2021 Jun;32(6): 821.

6.Thein MS, Ershler WB, Jemal A, et al. Outcome of older patients with acute myeloid leukemia: an analysis of SEER data over 3 decades. Cancer. 2013;119(15): 2720–27.

7.Gilliland DG, Griffin JD. The roles of FLT3 in hematopoiesis and leukemia. Blood. 2002;

100(5):1532-42.

8.Papaemmanuil E, Gerstung M, Bullinger L, et al. Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med. 2016 Jun 9;374(23):2209-2221.

9.Carow CE, Levenstein M, Kaufmann SH, et al. Expression of the hematopoietic growth factor receptor FLT3 (STK-1/Flk2) in human leukemias. Blood. 1996; 87:1089-96.

10.Kottaridis P, Gale RE, Linch DC. FLT3 mutations and leukaemia. Br J Haematol. 2003;122(4):523-38.

11.Kennedy VE, Smith CC. FLT3 mutations in acute myeloid leukemia: key concepts and emerging controversies. Front Oncol. 2020; 10.;10:612880.

12.Daver N, Schlenk RF, Russell NH, et al. Targeting FLT3 mutations in AML: review of current knowledge and evidence. Leukemia. 2019; 33:299-312.

13.Nagel G, Weber D, Fromm E, et al. Epidemiological, genetic, and clinical characterization by age of newly diagnosed acute myeloid leukemia based on an academic population-based registry trial (AMLSG BiO). Ann Hematol. 2017; 96:1993-2003.

14.Patel JP, Gönen M, Figueroa ME, et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med. 2012; 366(12):1079-89.doi:10.1056/NEJMoa1112304.

15.Gale RE, Green C, Allen C, et al. The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia. Blood. 2008; 111(5):2776-84. doi:10.1182/blood-2007-08-109090.

16.Krönke J, Bullinger L, Teleanu V, et al. Clonal evolution in relapsed NPM1-mutated acute myeloid leukemia. Blood. 2013; 122(1):100-8. doi:10.1182/blood-2013-01-479188.

17.Brunet S, Labopin M, Esteve J, et al. Impact of FLT3 internal tandem duplication on the outcome of related and unrelated hematopoietic transplantation for adult acute myeloid leukemia in firs remission: a retrospective analysis. J Clin Oncol. 2012; 30(7):735-41.doi:10.1200/JCO.2011.36.9868.

18.Pollyea DA, Altman JK, Assi R, et al. Acute myeloid leukemia, version 3.2023, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2023; 21(5):503-13.